The triple combination regimen of pertuzumab, trastuzumab and docetaxel is increasingly common because of its beneficial effects on human epidermal growth factor receptor 2 (HER2)-positive breast cancer [1–3]. Here, ERBB2 is linked to breast carcinoma.